logo
Share SHARE
FONT-SIZE Plus   Neg

Immunomedics Reveals Study Results For Radioimmunotherapy Of Colorectal Cancer

Biopharmaceutical company Immunomedics Ic (IMMU) Monday revealed that colorectal cancer can be safely, specifically and rapidly targeted with TF2 bispecific antibody and a radiolabeled peptide, with limited toxicity to the patient.

The company stated that TF2 is a bi-specific antibody created using the patented Dock-and-Lock conjugation technology. In addition to targeting the carcinoembryonic antigen expressed by many human cancers, TF2 has been engineered to recognize a small peptide that carries radioactivity. This allows the injection of radioactivity to be separated from the administration of the tumor-targeting bispecific antibody, a concept known as pretargeting.

The company further stated that the study results revealed that pretargeting has the potential advantage of delivering increased radiation dose levels selectively to the tumors while minimizing the body's exposure to radiation's harmful side effects.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Electric car maker Tesla Motors Inc. (TSLA), Wednesday reported a first-quarter loss that widened from last year, hurt largely by higher operating costs which offset an increase in revenues. Loss for the quarter were narrower than what Wall Street expected, while revenues came in line with estimates. Shares... GoPro Inc. (GPRO) has launched two new mobile video editing applications for its users. The two new mobile apps Quik and Splice will help users to manage, edit, and share all of the content from GoPro cameras and mobile devices. In February, GoPro had acquired two mobile video editing apps, Replay... Fast changing fashion trends have been hitting Aeropostale badly for the last several quarters, and at last it opted for Chapter 11 bankruptcy filing on Wednesday.
comments powered by Disqus
Follow RTT